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a review of the
international debate
Transgenic products have a number of contradictory aspects.
On the one hand, the genetic manipulation of plants makes
it possible to develop both products which contain
insecticidal toxins and can thus permit a reduction in the
use of pesticides that may harm the environment, as well as
foodstuffs with contents of vitamins and proteins that can
improve the social indicators of the developing countries.
On the other hand, however, questions have been raised about
the possible effects of transgenic products on biosafety and
biodiversity and the potential danger involved in consuming
them, and the various actors participating in the debate on
these products have widely different positions on their
commercialization. The process of negotiation and
subsequent approval of the Biosafety Protocol and the
controversies over acceptance of the safety first principle or
over the rules of the World Trade Organization (WTO) for
restricting the production and commercialization of
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I
Introduction
introduced into that of another, so that moving the genes
also moves their features and characteristics and new
substances or functions are produced. The resulting
organism has a new combination of genes which is not
found in nature and cannot be attained by natural means.
The use of these techniques makes it possible to increase
or block the amount of proteins produced by an
organism which, for example, does not produce them
or whose production it is desired to inhibit (OECD,
1999a).
Another application of biotechnology is the use of
techniques to recombine DNA. Scientists can isolate the
genes of different organisms, different species or a
single species and divide or join them and add or
transfer genetic material between different varieties
deliberately and at will. This technique has a well-
defined capacity for intervention. As the DNA is part of
the nucleus of cells, the genetic information is
transferred between unrelated organisms to produce a
new one. Thus, with the existing technology hereditary
information can cross the barriers between species
(OECD, 1999a and 1999b; Grace, 1997).
Through the breaking down of biological barriers
and crosses between species, transgenic foodstuffs or
organisms are obtained. The new organisms with the
desired genetic characteristics are a crop variety which
is identical to the traditional one but now incorporates
new genetic information.
2. The issues and actors in the international
debate
a) The issues
Biotechnological applications are designed to help
satisfy the growing food needs of the world’s
population. At the same time, however, scientists and
entrepreneurs warn that scientific progress, while
offering benefits to society, also presents risks and
challenges of an ethical, environmental and health-
related nature.
Ethical, because it is within their territories that
the indigenous communities of some developing
countries possess the ownership and knowledge of the
genetic resources found there. These countries and
communities are not taken into account, however, when
1. Background
New biotechnological research with economic
applications has been taking place for several decades
now. The rapid progress of biotechnology (“the genetic
revolution”) is often compared with the “green
revolution” of the 1960s and 1970s. The new
biotechnology1 has a direct relation with biosafety and
biodiversity, both of which are important tools for
enabling a country to achieve economical and efficient
agricultural development.
Genetic engineering techniques play a fundamental
role in the progress of agricultural biotechnology and
have a particularly strong impact on the inputs used in
agriculture and food production. Manipulation of the
existing genes allows agroindustrial enterprises to
develop new varieties of crops and processed foodstuffs
with a smaller consumption of energy or chemical
inputs.
The use of agricultural biotechnology has given
rise to great expectations, but also to uncertainty over
possible risks. There is concern over its possible
repercussions on human health and the environment.
Even though there is no evidence so far that
biotechnology makes foodstuffs any less innocuous,
there is continuing mistrust in society about consuming
products subjected to such techniques.
The Convention on Biological Diversity defines
biotechnology as “any technological application that
uses biological systems, living organisms, or derivatives
thereof, to make or modify products or processes for
specific use”. This definition covers a whole range of
techniques used in agriculture and the food industry,
such as DNA2 and reproductive techniques and gene
manipulation and transfer. Through their application it
is possible to modify foodstuffs more quickly and
precisely.
Genetic engineering techniques make it possible
to alter the inherited characteristics of living organisms
such as animals or plants. The individual genes are
extracted from the genome of one organism and
1
 Hereinafter, “biotechnology” will be used in the sense of the
modern or new biotechnology.
2
 The nucleic acid chain containing the genetic material governing
the development of cells and organisms.
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the enterprises that possess the relevant technology
share out the resulting benefits. The use of
biotechnology cannot be viewed solely from the
scientific standpoint, because when scientists intervene
they produce genetic combinations that may transgress
the laws of nature.
Environmental, because agricultural
biotechnological applications raise possible risks of
reducing biodiversity and affecting the biological
balance. Crops - plants and organisms - can be reduced
to a state of complete uniformity from the genetic
standpoint. Expanding the area devoted to a single type
of crop reduces the overall variety of crops and
contributes to the loss of genetic diversity, especially
in rural areas. There may also be a risk of developing
wild species which are resistant to insecticides or to
diseases and thus unbalancing the ecosystem.
Lastly, the fear that the consumption of transgenic
foodstuffs may be dangerous to health is due to the
fact that there is no convincing scientific evidence that
such foodstuffs really are harmless. The risks involved
include the transfer of toxins or allergenic compounds
from one species to another, the creation of new toxins,
or the appearance of unexpected allergic reactions. This
is one of the ever-present issues in the present debate.
The short length of time that has passed since the
introduction of these products makes it difficult to deal
with this problem, because of the insufficient evidence
available for determining whether transgenic foodstuffs
are a danger to human health or not.
The use of transgenic organisms in agricultural
production has revealed improvements in some of the
original characteristics, such as greater resistance to
certain pesticides or herbicides and to diseases or pests
(viruses, fungi, insects and parasites). Crops are now
better adapted to environmental conditions –such as
frosts, droughts and poor soils– which were
unfavourable when using traditional techniques; they
have a higher content of nutrients, vitamins, minerals
or proteins; their fat content is lower; the flavour, colour
or texture of foodstuffs is better, and they are easier to
prepare and store.
One of the contributions of genetic modification
is that it can introduce elements designed to lower the
risk of infection and reduce the use of chemical products
for pest control. Some experts note, however, that this
resistance can also represent a threat to biological
diversity, because farmers will tend to cultivate
genetically uniform plant varieties or the conservation
and/or use of traditional crops will be adversely
affected.
Another unfavourable result is the spread in the
earth of micro-organisms which can give rise to
biochemical changes and affect the balance of the
ecosystem. There is also the negative impact of
transgenic crops on the conservation of neighbouring
traditional crops, by pollinating them with genetically
modified elements and passing these on to future
generations of the crops. Furthermore, while
biotechnology has developed new and more powerful
pesticides and weedkillers which destroy pests and
weeds and prevent them from affecting crop
productivity, they may also endanger other plants which
are desirable for conserving biodiversity (Brañes and
Rey, 1999).
At the same time, the cultivation of transgenic crops
can cause socio-economic changes in less developed
countries by displacing labour from one of its principal
economic activities. In those countries, an important
source of employment is the cultivation of staple crops
such as maize, and the displacement of the labour force
employed in this can endanger the livelihood of a
considerable part of the population.
b) The actors
The participants in the international debate include
governments, biotechnology enterprises, scientists,
non-governmental organizations, farmers, consumers
and environmentalists; some of them are more critical
than others of the application of the new techniques.
These groups are not homogeneous and display
differences both among them and within the groups
themselves.
There are two main currents of opinion, with
opposing arguments, in the debates on the use of
biotechnology. One of them, which supports the new
biotechnology, is made up in particular of producers
and distributors; the other group, which rejects this
technology, is mainly made up of consumers and
environmentalists.
Those in favour of the continued progress of the
biotechnology industry emphasize that the greater
output will allow consumers to obtain food at lower
prices because of the lower production costs, the
reduced use of production inputs and chemicals, the
higher yields, and the availability of more
environmentally favourable production techniques. The
application of biotechnology to crops, they claim, has
given these greater resistance to pests, diseases and
adverse environmental conditions.
The biotechnology industry is run mainly by a
small group of transnational corporations, mostly
C E P A L  R E V I E W  7 5  •  D E C E M B E R  2 0 0 1204
TRADE IN  TRANSGENIC PRODUCTS: A  REVIEW OF THE INTERNATIONAL DEBATE  •  MARÍA ANGÉLICA LARACH
located in industrialized countries. These enterprises
develop and market products and processes and are
concerned with achieving efficient production and
making a profit. The high cost of biotechnological
innovation means that the world seed, fertilizer and
pesticide market is concentrated in only a few
enterprises, which, in their campaigns in favour of
transgenic products, lay great stress on the fact that only
small amounts of their inputs are needed in agricultural
production. The transnationals do not, however,
publicize the fact that they themselves are the main
producers of such agricultural inputs: they control 60%
of the pesticide market and 100% of the transgenic seed
market.
Distributors also gain from the advance of
biotechnology, since perishable transgenic foodstuffs
can be stored longer without deterioration.
Scientists do not take a united stance. They are
divided between those who defend the harmlessness
of transgenic foods, on the grounds that so far they have
not caused any major accidents in the areas of health
and the environment, and those who consider that such
foods involve potential risks. As public opinion is highly
sensitive to biotechnological matters, scientists must
redouble their research efforts in order to arrive at an
objective and impartial evaluation of their effects.
Those members of the scientific community who
are in favour of biotechnology consider that the use of
the new genetic techniques is an advance and that, if
they are properly used, they could benefit countries by
improving their crop yields, saving costs on inputs, or
improving production by increasing the content of
nutrients in foodstuffs. They also consider that
facilitating access to markets would help developing
producer countries to reduce their dependence on
imported staple foods, thus enabling them to combat
famines in depressed areas.
Consumers are not very well organized and, unlike
the scientists, they have only confusing information on
the risks and benefits of transgenic foods for health.
The information they receive is incomplete, since the
producing companies do not always publicize the
transgenic origin of their products, thus further
increasing the degree of uncertainty. They consider that
they have the right to receive innocuous and good-
quality foodstuffs and to know what inputs were used
in their production. They demand transparency,
education and true, adequate and timely information
on the benefits and risks for their health. They do not
always believe that the results of scientific studies are
true. They are very reluctant to accept agricultural
products that damage the environment. They claim that
regulations are either non-existent or inappropriate, and
they demand more participation from the governments
responsible for regulating the production and marketing
of the new products.
Advances in biotechnology help to create new
foodstuffs of agricultural and agroindustrial origin, and
since these are aimed at society as a whole, greater
attention should be paid to consumers’ complaints.
Society demands that governments should detect and
appraise possible health risks before allowing
transgenic foodstuffs to be placed on the market.
Environmentalists are generally against the
production of these foods because they consider that
they represent risks for the environment and
biodiversity and not enough studies have been made of
the possible dangers. This group is also joined in this
attitude by the non-governmental organizations, which
take an active part in these debates.
The debates stress the need to carry out more
careful studies of the effects that the application of
genetic engineering techniques may have on human
health, on the environment and on agriculture, and they
emphasize that the task is how to produce more and
provide real benefits to society.
The studies on the effects of incorporating
biotechnological applications in the agricultural
environment have centered mainly on the developed
countries, especially the United States and the Western
European countries. The differing interpretations on
the harmlessness of transgenic products which have
emerged in the developed world, however, have given
rise to concerns which have spread to the developing
countries in advance. With the appearance of the first
transgenic products, some governments have shown
more concern than others, regulating transgenic crops
in experimental fields and providing information to
ensure that there are no risks even before the modified
products are placed on the market.
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The surprisingly rapid growth in the area planted with
transgenic crops faces agricultural producers with an
enormous challenge. According to James (2000), the
total area planted with such crops in the world increased
from 1.7 million to nearly 40 million hectares between
1996 and 1999. The 44% increase between 1998 and
1999 was accounted for mainly by four industrialized
and four developing countries.3 The total area planted
with transgenic crops in the United States came to 29
million hectares in 1999: i.e., almost 80% of the world
total (table 1).
In the year 2000 this area increased once again,
but more slowly. The 11% increase over the previous
year was equivalent to 4.3 million hectares, of which
3.6 million (84%) corresponded to developing
countries, with the remaining 0.7 million (16%) being
accounted for by industrialized countries. Between
1996 and 2000, the area planted with such crops
increased by a factor of 25 and the number of countries
involved rose from 6 to 13. Today, these crops have
spread to Australia, China, India, Malaysia and
Thailand.
The United States, Canada and Argentina
accounted for 98% of the total area planted with
transgenic seeds in the year 2000. In that year, 100%
of the area planted with such crops corresponded to
soya beans, maize, cotton and canola. Of the 273 million
hectares devoted to these four products in the world,
16% corresponded to modified crops (table 2).
In 2000, there were 26 million hectares of modified
soya in the world: 58% of the total area planted with
transgenic seeds and 19% more than in the previous
year. Thus, of the 72 million hectares of soya planted
in the world, 34% corresponded to the modified variety.
Between 1999 and 2000 the total area planted with
modified maize in the world went down from 11.1
million hectares to 10.3 million, so that of the 140
million hectares planted with maize in the world, 7%
corresponded to the transgenic variety. The reductions
in the United States and Canada were partly offset by
increases in Argentina and South Africa. In the year
2000, the United States Environmental Protection
Agency (EPA) warned growers of modified maize that
they must reserve between 20% and 50% of their
cultivated area for traditional products in order to help
stop the increase in transgenic crops.
Cotton has an important place among transgenic
crops: between 1999 and 2000 it increased by 1.6
3
 South Africa, Argentina, Australia, Canada, Spain, the United
States, France and Mexico.
TABLE 1
Selected countries: Area of transgenic crops,
by country,a 1997-2000
(Millions of hectares)
1997 1999 2000 2000/1999
(%)
United States 8.1 28.7 30.3 6
Argentina 1.4 6.7 10.0 49
Canada 1.3 4.0 3.0 -25
Australia 0.1 0.1 0.2 100
Mexico 0.1 0.1 < 0.1 0.0
Europe ... ... ... ...
Total 11.0 39.9 44.2 11.0
Source:  Agrodigital,  11-05-99, Bioinfo Centre, http://
www.biotechknowledge.com; reference 2781.
a Excluding China. Inclusion of China would increase the total
area for 1997 to 12.8 million hectares.
TABLE 2
World: Area of transgenic crops, 1996-2000
(Millions of hectares)
Crops 1996 % 1999 % 2000 %
Tomatoes 0.1 4 ... ... ... ...
Potatoes ... ... 0.1 ... ... ...
Soya 0.5 18 21.6 54 25.8 58
Maize 0.3 10 11.1 28 10.3 23
Tobacco 1 35 ... ... ... ...
Cotton 0.8 28 3.7 9 5.3 12
Canola 0.1 5 ... ... 2.8 6
Total 2.8 100 39.9 100 44.2 100
Source: James, 2000.
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million hectares (43%). Of the 34 million hectares
planted with cotton in the world, 16% correspond to
transgenic cotton. The increases observed are mainly
due to the larger areas planted in the United States (55%
and 72% in 1999 and 2000 respectively). China also
increased its area of this crop, but only moderately
(10%); it was followed by Mexico, Australia, Argentina
and South Africa.
China was one of the first countries to produce
transgenic crops. It began in 1992, and this activity has
come to occupy an important place in the country. In
1999 it planted some 750,000 hectares of such crops
(mostly cotton), and it is estimated that in 2000 the
total area came to 1.2 million hectares.
The situation in Europe is different, and the areas
planted with transgenic crops are only small. Spain is
an importer of transgenic products, especially modified
maize, and it has the largest experimental plantations
of genetically modified products in Europe, with over
20 experimental stations. In 1999 it was the leading
producer of modified maize, with 10,000 hectares
planted with this crop (0.02% of the world total). In
the year 2000 the total area planted with transgenic
crops went down in Europe, but two new producers
entered the scene: Romania with soya and potatoes,
and Bulgaria with maize.
In recent years the European Union has approved
only a few experimental plantations, and only for a
limited number of transgenic crops. The small number
of authorizations granted by the EU, compared with
the number granted by the United States, Canada and
some Latin American countries, is putting the European
authorities under pressure. In 1999 the United States
approved 35 modified crops and the EU countries only
nine, while Japan alone authorized seven.
Early in 2001, the European Parliament approved
the unification of the different national regulations and
authorized the fixing of deadlines and labelling
standards, which suggests that it intends to put an end
to the moratorium on the marketing of modified
agricultural products. This new attitude could begin to
bring the positions of the European countries closer to
that of the United States.
2. Production in Latin America
The area planted with transgenic crops in the developing
countries increased by 14% in 1997, 18% in 1999 and
24% in 2000. In the latter year, a quarter of the total
world area planted with such crops corresponded to
the developing countries (10.7 million hectares).
Between 1999 and 2000, the area of transgenic
crops in the developing countries increased from 7.1
to 10.7 million hectares (51%), the countries which
contributed most to this increase being China and
Argentina, with 0.5 million and 10 million hectares
respectively.
In 1998 there were two outstanding developing
producers of transgenic crops: Argentina, with 15% of
the total area, and Mexico, with nearly 1%. Argentina
has the largest area of transgenic crops in Latin America
and is the second largest producer of them at the world
level, with 4.3 million hectares out of a world total of
28 million in 1998.
Soya accounts for the largest number of hectares
of transgenic crops, and Argentina is the third largest
producer of transgenic soya in the world. Over the last
five years the area devoted to this crop has grown by
29%, while over the last ten years it has doubled,
reaching 7.4 million hectares in the year 2000. Of the
4.2 million hectares by which world production of
transgenic soya increased in that year, 2.7 million
corresponded to Argentina and 1.5 million to the United
States; in 2000 the total area planted with soya was 9.6
million hectares in Argentina and 30.2 million in the
United States.
The cultivation of modified maize, for its part,
increased from 5% to 20% between 1999 and 2000 in
Argentina, and this growth, together with that registered
in South Africa, partly offset the decline in the United
States and Canada.
Mexico has one of the highest levels of biodiversity
in the world, and its protection is a priority matter. It
has authorized some 150 applications to release genetic
organisms in fields, greenhouses and laboratories, of
which 33 corresponded to maize, 28 to cotton, 15 to
tomatoes, 13 to soya and 3 to wheat, among other
species.
In Brazil, biotechnology is applied especially in
agriculture. That country is the second largest producer
of soya in the world, with an output of 30.5 million
tons in the 1998-1999 period. Brazil has great
biodiversity, and the government seeks to protect it by
limiting or prohibiting modified crops until
environmental impact studies are carried out. At the
end of 2000, however, the situation seemed about to be
reversed with the Ministry of Agriculture’s
announcement that it would permit the production of
those crops for which there was a demand.
In Chile there are nearly 5,000 hectares of
transgenic seed plantations, mostly run by foreign firms.
Land is available for their reproduction, and there is a
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possibility of increasing exports of such seeds in coming
seasons. The country has been importing genetically
modified seeds of maize, soya, sugar beet, canola and
tomatoes since 1992 but only for reproduction and
export, since their local sale is not yet allowed (Manzur,
1999). The production of transgenic foods for local
consumption is not allowed, but such foods are imported
without any knowledge of the origin of the inputs they
contain. A high percentage of the imports of foodstuffs
containing soya and maize come from Argentina and
the United States, without any indication of whether
they contain manipulated genes.
Uruguay and Paraguay take a cautious stance in
this respect. In 2001 the Ministry of Stockraising,
Agriculture and Fisheries of Uruguay authorized the
experimental planting of transgenic products, but not
their sale. In Paraguay, consideration is being given to
an application to allow Argentina and the United States
to introduce transgenic soya and maize seeds, but so
far the country is considered to be free of transgenics
(The Biotechnology Knowledge Center, 1999a and
1999b).
Costa Rica has a rich diversity of biological
resources and uses biotechnological means to conserve
them. It is estimated to possess 5% of the biodiversity
existing in the entire world (Brañes and Rey, 1999).
The use of pesticides on banana, coffee and rice
plantations trebled between 1993 and 1996, causing
health problems for workers and contamination of land,
water and animals.
3. Trade
Between 1995 and 1998, world sales of transgenic crops
soared from US$ 84 million to nearly US$ 2.3 billion,
and in 1999 they amounted to US$ 3 billion (Krattiger,
1999), while they are expected to reach US$ 20 billion
by 2010 (James, 1999). The most important market is
for seeds, followed by microbiological agricultural
inputs. There is a growing trade in new types of fruit
and vegetables marketed directly by the companies that
develop them (Jaffé and Infante, 1996).
Authorizations for the marketing of transgenic
products include such items as soya, canola, cotton and
potatoes. The countries which market the largest
quantities of modified foods are the United States,
Canada and Australia, together with some Latin
American countries such as Argentina and Mexico. The
marketing of such products has got off to a slow start
in Europe, where the sale of only 18 transgenic products
has been authorized between 1992 and 1998.
The United States leads the way in the use of
genetic engineering in the production of modified soya,
maize, wheat and cotton for export. It accounts for
nearly 90% of the world trade in transgenic soya and
maize. In transgenic soya alone it exports 40% to
Europe. It exported some 9 million tons of modified
and unmodified soya in 1998 (The Economist, 1999).
United States exports of modified maize to the
European Union went down from 2.7 million tons in
1995/96 to only 100,000 tons in 1997/98 because of
the mistrust of EU consumers over possible effects on
health.
Japan imports transgenic foods, mainly from the
United States. It currently imports 29 varieties of seven
crops: maize, soya, colza, potatoes, cotton, tomatoes
and sugar beet (Programa Chile Sustentable, 1999).
Free trade is menaced by national regulations such
as production and import controls, limitations on access
or sales, or direct prohibitions of entry into markets.
There is an ever-present danger that food safety
regulations will be adopted in response to the pressures
of consumers and defenders of the environment.
The increase in opposition to the consumption of
transgenic foods has affected the destinations of
Argentina’s soya exports. In 1999, 40% of the seeds
and some 60% of soya pellets went to Europe, but since
then they have gone to countries where consumers are
not opposed to the consumption of such foods, such as
India, China and some Latin American countries.
Other Latin American countries have expressed a
desire for well-defined guidelines on trade in foodstuffs
obtained through biogenetic applications, because they
are aware that they have an asset –biodiversity– which
they want to conserve. They are also producers of
various organic products (fruit and vegetables) which
have a better chance of acceptance than transgenics.
It is not expected that the production and marketing
of transgenic foods can be stopped. On the contrary,
some new ones will come on the market soon, now with
incorporated vaccines. This could endanger the foreign
exchange income from exports of traditional foods if
developing countries, including some from Latin
America, replace some products with others that are
similar but are obtained through in vitro techniques
using transgenic organisms.
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III
The Protocol on Biosafety and the WTO rules
1. The Protocol on Biosafety
a) Background
From the very beginning the application of
biotechnology to agricultural crops and foodstuffs has
given rise to a debate on their impact on agriculture,
the environment and human health. It is therefore not
surprising that the scientific, socioeconomic and
environmental issues connected with biological and
biotechnological resources come up frequently in the
main forums of negotiation.
Environmental concerns were expressed at the
Earth Summit (Rio de Janeiro, 1992) and were given
concrete form in the Rio Declaration on Environment
and Development, in Agenda 21, and in the Convention
on Biological Diversity (CBD). The negotiations on the
Protocol on Biological Diversity began in 1996, and
six meetings have been held, the first at Aarhus,
Denmark, and the latest, in February 2000, at Montreal,
Canada.
The CBD lays down that the countries must consider
the form and need for a Protocol to regulate procedures
regarding the transfer, handling and use of transgenic
organisms which could have harmful effects on
biodiversity and its components. The aim was to create
an international juridical framework for the application
of measures to ensure complete safety or at least
minimal risks so that this technological advance will
not affect biodiversity, already threatened today by over-
exploitation of resources and degradation of
ecosystems, through the danger of homogenizing crops.
The European Union countries have defined
standards, domestic laws and EU-wide laws concerning
human health and the environment. They included in
them regulations on agricultural production, and within
them rules on transgenic foods, whether for
experimental purposes or commercialization, in order
to avoid negative repercussions on themselves and other
States.
At the same time, the difficulty of harmonizing the
different national interests, regardless of whether
countries are EU members or not, has meant that
biodiversity has ceased to be the common property of
the human race and has become instead the property of
States, which have now been given responsibility for
preserving it. As a result, it was decided that States also
had territorial responsibilities in regulating their
domestic standards.
In 1999 the Ministers of the Environment of the
EU tried to check the spread of transgenic organisms
and adopted a “policy declaration” which was seen as
a de facto moratorium on new crops and authorizations
for their commercialization, to remain in force until
research findings were more conclusive. This decision
causes conflicts with the United States and with
companies producing transgenic foods, and could give
rise to complaints to the WTO.
By including the safety-first principle in the
Protocol, the European Union can block the sowing of
seeds containing modified genes or prohibit their
importation on the grounds of doubts or lack of
sufficient information. The Ministers of France, Greece,
Italy, Denmark and Luxembourg defend the
moratorium on the introduction of new crops. Countries
with a more favourable attitude to the marketing of such
products are Germany, Spain, the Netherlands and the
United Kingdom, although Germany and Spain, which
have only incipient markets in this respect, did not
oppose the moratorium. Moreover, some countries do
not wish to lose the chance of doing business with the
main vendors of biotechnology and its products, nor
do they wish to face possible sanctions applied by the
WTO.
In the United States, in order to put a transgenic
agricultural food product on the market it is necessary
to comply with procedures laid down by three Federal
agencies: the U.S. Department of Agriculture, the Food
and Drugs Administration, and the Environmental
Protection Agency. Responsibility in health matters lies
with the National Institute of Health and a division of
the Department of Agriculture which supervises food
safety.
Some of the developing countries are in favour of
regulating trade in transgenic foods on the grounds that
little is known about their effects on health and the
environment. They are worried that in the future
dependence on imported biotechnology will be added
to their already high degree of subordination to foreign
scientific knowledge and outside management of new
technology. Acceptance of an international law
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regulating cross-border trade could avoid their land
being used as testing grounds for such crops and thus
obviate possible environmental risks.
b) Positions and negotiations in the debate
The negotiations in Cartagena and Montreal were
difficult, and countries with diametrically opposed
positions had to give way in their demands in order for
the Protocol on Biosafety to be adopted. The discussions
were continued in other international forums with
different actors, including representatives of consumers
and environmentalists.
Biotechnology has raised the value of genetic
resources and made it advisable to establish
international regulatory frameworks. The Convention
on Biological Diversity called upon States to consider
the possible forms of an international instrument to
regulate the use of the new techniques. The Protocol
on Biosafety, which is an international instrument, only
covers the cross-border movement of products and asks
its signatory States to complement it with national
legislation.
The difficulties in arriving at a consensus caused
the countries to form groups according to their interests
and opinions. Five such negotiating groups were
formed: i) the Miami Group, made up of the United
States, Canada, Australia, Argentina, Uruguay and
Chile; ii) the European Union countries; iii) the
Compromise Group; iv) countries with a high level of
biodiversity, such as Switzerland, Norway, New
Zealand, Mexico, Japan and South Korea; and v) the
Like-Minded Group, made up of developing countries
such as China and countries from Africa, Asia, Latin
America and the Caribbean, excepting those already
mentioned earlier.
The negotiations began with matters connected
with biodiversity and the safety of human health and
the environment and continued with the evaluation of
risks in the handling, use and transport of transgenic
products, socioeconomic implications, responsibility
for damage or accidents, institutional capacity, and the
exchange of information. With time, trade-related
aspects were also dealt with, such as cross-border
movements, the safety-first principle, labelling, and the
relation with other international agreements, especially
with the WTO in the Sanitary and Phytosanitary
Measures (SPM) and Technical Barriers to Trade (TBT)
agreements.
In the position of the EU countries and a number
of developing countries, the Protocol on Biosafety was
linked with agreements on the environment. It was
feared that controls on transgenic foods would become
a dead letter and that trade-related measures would take
precedence over environmental and sanitary measures,
so the members of this group sought to balance
environmental measures with trade-related measures
and make the former complementary to those of the
WTO.
The European Union countries considered that it
was necessary to weigh risks under the safety-first
principle on the basis of scientifically proven evidence.
That principle, which is not regulated by international
law, does not allow the circulation of foodstuffs unless
it is known for certain that they do not have any adverse
effects on health or the environment. The countries
which are in favour of international rules reject the
importation of transgenic foodstuffs unless they have
passed the risk evaluation tests carried out by national
and EU authorities. The European Commission does not
permit unilateral prohibition of a crop unless there is
new evidence that it is harmful.
The members of the European Union have striven
to achieve a common position and set of rules on
modified organisms, as they have been obliged to
regulate the liberation of such organisms (for sale,
experiments or trade) in their territories. The stricter
European rules, compared with the absence of suitable
legislation in other markets, has led EU companies with
biotechnological interests to experiment in unregulated
markets, or else in their own markets, but with prior
authorization. The differing opinions of governments
on the effects of the different national standards of food
safety make it difficult to advance in the negotiations.
In the year 2000, the European Commission did
an about-turn in its position on the moratorium existing
since 1998 on authorizations for new transgenic
products: it now admits that such a moratorium is an
illegal and unjustified measure which must be lifted,
and it plans to adopt some new proposals, but in return
for medium- or long-term licences the biotechnology
companies must accept stricter rules which include risk
evaluation, labelling and closer controls over trade.
The Miami Group countries prevented the approval
of a regulatory framework which would prevent the free
trading of transgenic foodstuffs and derivates thereof.4
The Group was worried that the safety-first principle
could be used as a legal barrier to trade even when there
4
 As it has not ratified the Convention on Biological Diversity, the
United States does not have voting rights in the negotiations on
the Protocol.
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was no sound scientific evidence to back it up. The Group
was also reluctant to include labelling in the Protocol,
although this is an essential element in the safety-first
approach to commercialization. The United States
position is that only those transgenic foods which are
substantially different from traditional ones warrant
regulation. Otherwise, they say, the European Union
could take advantage of the situation to demand that all
modified foods are labelled to show the genetic origin
of the product: the WTO trade regime should therefore
prevail over the Protocol on Biosafety (Kerr, 1999).
The negotiations to define rules on trade in
transgenic foodstuffs failed at the Cartagena meeting
in 1999. Some countries feared that the WTO rules would
come into conflict with those of the Protocol, since they
saw that the environmentalist group was not fully
familiar with the international trade rules. If the Protocol
were accepted, the international movement of
transgenic foodstuffs could be limited for human, plant
or animal health reasons or for alleged damage to the
environment. That should not be allowed to create
barriers to agricultural trade or to weaken the Sanitary
and Phytosanitary Measures Agreement.
Early in the year 2000, the Miami Group prevented
other governments from demanding prior authorization
for imports for re-export. The negotiations ground to a
halt, and a year later, at Montreal, the Miami Group
and the European Union gave way on their initial
positions and assumed a compromise position. 135
States voted in favour of the Protocol, which, when
ratified, will be added to other environmental treaties
for regulating trade.
c) The Protocol and its significance
A distinction may usefully be made between two cases
of introduction of transgenic organisms into the
environment: one is their incorporation into cultivation
(seeds, for example), while the other is their
incorporation into the processing and consumption of
human or animal food (grains, for example). This
distinction will make it easier to understand certain
aspects of some of the principles included in the
Protocol.
This lays down that each country can adopt its own
regulations on transgenic foodstuffs, and those
regulations may be more demanding than those of the
Protocol itself, but they must be notified to the other
countries. In order to share that information, the
Advance Informed Agreement (AIA) mechanism was
set up and forms a key element of the Protocol.
The AIA is merely a prior control before
authorization is given for human consumption of
modified foods in importing countries: i.e., it is a
notification between countries. This Agreement requires
an authorization from the importing country before the
first cross-border movement of the transgenic organism
in question. This allows information to be obtained
about countries which reject transgenic foods. The
application of the AIA also makes possible an evaluation
of risks and possible adverse effects and, if the latter
are present, denial of access based on scientific
evidence, in order to avoid unjustified trade barriers.
The AIA makes possible restrictions on the trading
but not on the cultivation of transgenics. As from 2002,
exports –mainly made by the United States, Canada
and Argentina– must obtain a prior permit from the
importing country and notify it to a United Nations
regulatory body.
This is where the first responsibility of the
exporting country arises, which must notify its intention
to export the goods, and that of the importing country,
which must develop and announce its regulations. The
exporter can opt between a national regulatory system
consistent with the Protocol or a system regulated by
the Protocol itself. The AIA allows the importing country
to veto the application even if scientific evidence is
submitted by the exporting country (Cosbey and
Burgiel, 2000).
In the case of transgenic organisms destined for
processing and consumption, the AIA is not mandatory.
Through its risk evaluation the importer can request
additional information, accept access with or without
conditions, prohibit entry or extend the time limit for the
entry of the modified organism. Although the AIA does
not cover agroindustrial products whose production
processes have involved some transgenic organism, this
is a consumer and environmental protection element when
solid scientific evidence is lacking.
The Protocol includes the safety-first principle, in
order to protect the environment from the reduction of
biodiversity and to protect the health of consumers.
Regulation of cross-border movements of transgenic
agricultural foodstuffs obviates environment and health
risks. Other biosafety aspects must be covered by
national laws.
The safety-first principle is a government option
for rejecting access without being penalized at the
international level. It allows the country to receive the
information on use and safety required when transgenic
organisms are introduced into the environment and
requires notification among the countries when
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applying the AIA. It also allows the application of
restrictions and the requirement for guarantees for trade
in transgenics on the grounds of insufficient scientific
evidence and the assumption that there may be a risk
to biodiversity or human health.
The safety-first principle was achieved through the
mutual support existing between environmental and
trade instruments, without the former being
subordinated to multilateral trade agreements.
Biological diversity and food safety do not prevail over
the WTO rules, and vice versa. The Cartagena Protocol
is based on the safety-first principle and the WTO rules
on scientific evidence.
The Protocol must not affect the rights and
obligations of governments under other international
agreements (of the WTO or any other nature). With
regard to trade, it does not mean any change in the rights
and obligations entered into under an international
agreement, including the SPM and TBT agreements. The
controls on trade in transgenic products permitted under
the safety-first principle reverse the burden of proof, in
that stricter controls can be applied if there is no certain
scientific proof that the products are free of risk.
When an activity is begun it must be shown that its
effects are harmless to the environment; otherwise,
those effects are subject to controls and can lead the
country concerned to impose higher standards than
those provided for in other international agreements,
as a sovereign right. The European Commission
considers that every member of the WTO has the right
to establish the level of protection it sees fit, especially
as regards the environment and human health. The
United States, however, rejects the view that the
European Union’s safety-first principle should be
accepted as a legitimate trade barrier, arguing that the
question must be settled by having recourse to science,
which is not yet capable of assuring that transgenic
products will be safe in the future.
2. The WTO rules
One of the functions of the WTO is to settle trade disputes
among its members. With regard to the safety of
modified foodstuffs, it offers some principles that can
be used when countries are faced with different
interpretations of how to protect consumers.
Although the members of the WTO have not given
it a mandate to develop food safety standards, it does
have rules to prevent members from using unnecessary
and unjustified trade barriers. These rules are to be
found in the SPM, TBT and Trade-related Intellectual
Property agreements and in the exceptions to GATT,
article XX b) and g).5
Under article XX of GATT, countries have the right
to establish their own environmental and food safety
rules. Measures adopted under this right, however, must
be consistent with the principles of GATT: absence of
discrimination between nations and national treatment
once an import enters the national market. In the case
of a biotechnological product, however, some actors
argue that the production process is an important
element also. If the rules on trade include production
processes, using the exceptions in article XX of GATT,
the justification for the latter should be scientifically
proved, otherwise an amendment to that article would
be needed (ECLAC, 1998).
There is no commitment in the WTO regulating trade
in transgenic products, nor are there any international rules
governing their trade according to their method of
production. The rules on international trade deal with trade
in goods and not the production process, unless the latter
affects safety and endangers the natural resource in question
or human and animal health.
There are arguments both for and against the
desirability of amending article XX of GATT to permit
the application of trade measures to production
processes. This is a point which will have to be
discussed and settled in future negotiations, as also the
question of whether the Protocol should include only
transgenic micro-organisms or should also cover
production processes which use biotechnological
techniques in some part of the production chain.
National regulations can lead to discrepancies
among the parties. Those countries which consider that
a product obtained by traditional production methods
and one obtained through the use of biotechnology are
basically similar insist that the WTO agreements are
adequate for settling differences. Those which consider
that they are different products because the production
process is different, however, complain of the lack of
regulation of trade in biotechnological products.
The idea of annexing the Protocol to the WTO
agreements was defended by the Miami Group, which
respects the agreements of that organization. The Group
proposes that differences on trade in transgenic products
should be settled within the WTO, not through special
agreements. This matter is down for discussion at the next
round of negotiations of the organization (WTO, 1999).
5
 This allows governments to adopt trade measures which are
necessary in order to protect human, animal or plant health and to
ensure the conservation of exhaustible natural resources.
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Other countries use the safety-first principle to
justify protectionist measures. The European Union has
asked the WTO to clarify the use of that principle and to
extend its application to the whole framework of the
organization. It argues that transgenic products represent
a new technology which justifies the use of the principle,
because the prevention of possible risks and the
preservation of the environment should come above trade
liberalization. Crops incorporating modified genes are
seen by the EU members as a potential source of danger.
So far, the WTO has condemned the European
Union’s prohibition of the importation of meat treated
with hormones, the Australian ban on Pacific salmon,
and Japan’s requirement that a variety of fruit should
be subjected to tests because there is no scientific
evidence that its consumption is harmless. These two
factors –solid scientific evidence or, in its absence, the
application of the safety-first principle– cause tensions
in the trade negotiations.
New restrictions on trade can cause friction with
the multilateral trade system. According to the WTO,
the SPM and TBT agreements provide the necessary basic
guidelines for negotiating regulations on trade and
labelling, but when these agreements were signed, in
1994, the question of transgenic products was not under
negotiation. The two agreements in question seek to
regulate trade restrictions arising from the
indiscriminate use of technical measures to safeguard
human health, the environment and national interests,
as well as to harmonize national food quality standards.
a) The Agreement on Sanitary and Phytosanitary
Measures (SPM)
This Agreement, signed at the Uruguay Round,
regulates the application of sanitary and phytosanitary
measures. It applies to all measures for the protection
of human health that could directly or indirectly affect
international trade. It refers to regulations on the
harmlessness of foodstuffs and allows governments to
impose temporary internal and international measures
if such harmlessness and the sanitary control of animals
and plants are not assured.
The SPM Agreement allows governments to regulate
trade by applying national measures which are stricter than
international standards. In order to do so they must
scientifically prove that the international standards provide
less sanitary protection and must carry out a risk evaluation;
otherwise, there could be a flood of sanitary and
phytosanitary measures which would impede trade flows
(WTO, 1996).
There are important differences between the SPM
Agreement and the Protocol on Biosafety. One
difference is in respect of risk. The Agreement
recognizes that a level of risk exists, but does not
stipulate what constitutes a risk, and it promotes
systematic risk evaluations, but does not say how to
manage them; in order to apply the proper level of risk
governments review similar cases in other countries.
In contrast, the Protocol indicates what a risk is and
how to manage it, and in the absence of a scientific
basis it allows the use of the safety-first principle for
prohibiting or restricting an import.
The SPM Agreement allows the adoption of
provisional measures when the scientific evidence is
insufficient, whereas the safety-first principle is relatively
more restrictive for consumers. The Protocol permits the
importer to request the exporter to carry out a risk
evaluation in order to take decisions, whereas the
Agreement determines in advance what constitutes a risk
and how to calculate it (Cosbey and Burgiel, 2000).
On the basis of new scientific information, the
Protocol permits importers to review and change a
decision on the cross-border movement of transgenic
products, whereas the measures of the SPM agreement
are more ambiguous. Under the WTO, the rules do not
judge whether there is suitable scientific evidence or
what constitutes the best evidence in respect of a
transgenic foodstuff. At the request of the WTO itself,
this function has been transferred to the Codex
Alimentarius Commission, which is trying to formulate
general rules on the harmlessness of foodstuffs, to
control biotechnological foodstuffs and to develop
voluntary international food standards to be submitted
to governments for their acceptance and use in the
application of the SPM and TBT Agreements.
The rules prepared by the Codex Alimentarius
Commission should make it possible to judge whether
national rules inhibit international trade flows. If the
national regulations are not fully justified in accordance
with the international rules of the Codex, the dispute
must be settled by the WTO.
b) Agreement on Technical Barriers to Trade (TBT)
The TBT Agreement incorporates the technical rules of
national standards and regulations, regulates food quality
requirements and obligations not covered by the
Agreement, and includes technical prescriptions resulting
from measures on food safety, inspection and labelling.
In accordance with the rights and obligations laid
down in the TBT Agreement, countries can impose
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technical standards with legitimate intentions, provided
that the requisites thus demanded do not constitute
barriers to cross-border trade which are more restrictive
than is necessary in order to comply with the objectives
pursued. Among the contributions of the Agreement
are the establishment of international principles for the
elimination of unjustified trade barriers, avoidance of
the creation of new obstacles, provision of elements
for the development of international standards, and the
possibility of raising national standards to international
levels.
The Agreement does not give a clear and precise
definition of the meaning of international standards for
transgenic foods, nor does it provide for the equitable
distribution of national needs. The scant information
available means that the standards only reflect the
measures of a few countries. The Protocol on Biosafety
should give a precise definition of standards at both
the national and international levels.
The Codex Alimentarius Commission is
considering the advisability of adopting an international
standard for the labelling of transgenic foods, based on
substantial equivalence: i.e., whether a transgenic
organism is substantially equivalent to the original
foodstuff. The labelling requirements would seek to
ensure that the chosen standards support the right of
consumers to be informed and given a free choice, to
know what a foodstuff contains, and to be informed of
the inputs used in the production process. However,
this would require that the life cycle of the foodstuff be
kept constantly in view, which is no easy task.
Moreover, even if it were possible to follow up every
stage of the production process, not all countries would
be in a position to comply with that requirement.
The United States FDA does not support special
labelling and argues that, if there is no scientific certainty
that the incorporation of a transgenic product alters the
composition of a foodstuff and represents a danger to
health, special labelling should not be obligatory. It does
not reject voluntary labelling, but it does not wish to
establish a compulsory distinction between a transgenic
and an original foodstuff unless there is a substantial
difference between them. In some countries, trade
problems have arisen due to domestic pressures to use
labels as a condition for access to the market.
The Protocol does not aim to physically separate
genetically modified products from the rest. The
differences over labelling have been partly solved
because the United States has yielded to the European
Union’s pressures that labelling should be compulsory.
This is just the starting point for the reconciliation of
interests and the beginning of a new stage in the
negotiations. Compulsory labelling is also a matter of
concern for Brazil and Argentina. The Canadian
Government is analysing whether it should introduce
new regulations in this respect, since its position is
similar to that of the United States. In Japan, special
labelling has been obligatory since April 2000.
The European Commission does not consider
special labelling to be necessary, but the European
Parliament does demand complete information in order
to differentiate between products and considers that
more drastic measures should be taken to regulate
transgenic crops. Some countries of the European
Union, in contrast, give priority attention to
biotechnology, the introduction of new transgenic foods
on the market, the storage and shelf life of products, or
a responsible approach to food safety.
The main exports of transgenic products from the
United States to EU countries consist of wheat, cotton
and soya: precisely those products over which there
are differences. For the United States, these do not raise
any health risks. However, some European companies
have stopped using them as inputs in their production
processes because they are afraid they may contain
modified organisms.
European environmentalists continue to fear that
in the long run there will be negative effects on the
environment. They argue that consumers are being
deprived of information on potential risks and consider
that governments should require all transgenic foods
to be specially labelled. They claim that the rejection
of compulsory labelling by some biotechnology
industries shows that they have no confidence in their
own products.
Generally speaking, national and international
legislation on the control of transgenic organisms is
still sparse. Demands to the government by consumer
groups and non-governmental organizations for sure
and effective control of the foodstuffs offered on the
market are stronger in many developed countries than
in the developing countries. In this respect, there are
proposals for the establishment of a governmental body
with suitable technical and economic capacity for
reviewing food imports and verifying the truth of the
information printed on their packages.
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Final considerations
Modern biotechnology should be seen as a
complement to and not a substitute for traditional
agricultural techniques. Its use involves human
intervention to move genes between different
species. The current uncertainty about consuming a
transgenic foodstuff or a hybrid –which is also the
result of genetic modification, but within the same
species– applies to the former but not to the latter.
Biotechnology is simply a tool for solving some
agricultural problems. Its possible environmental, sanitary
and socioeconomic risks have caused concern within
society. The risks to human health are more generally
shared and similar among countries, but the environmental
risks need to be studied case by case because the effects
of applying this new tool –both positive and negative–
vary from one situation to another.
These techniques offer possible solutions for
current problems such as developing agriculture and
the food industry and satisfying the nutritional needs
of a growing population. This can be achieved, at least
in part, if a new generation of food crops incorporating
new characteristics and providing advantages over
traditional similar foods can be successfully introduced.
In order to decide whether it is beneficial or not to put
a transgenic foodstuff on the market, it is necessary to
provide the public with more information on the advantages
and biological safety of consuming it. Active participation
by consumers in the corresponding debates and their
guidance with information that can be readily understood
by them would reduce uncertainty in this respect, but the
lack of finance for establishing the necessary information
networks makes communication difficult, especially in the
developing countries.
The absence of rules on biotechnological foods in
international trade gave rise to a series of rounds of
negotiations which finally ended when the countries with
opposing positions gave way. The approval of the
Protocol on Biosafety showed that when the parties gave
way on their positions trade interests were balanced with
environmental concerns.
The Protocol requires countries to adopt domestic
legislation, develop a juridical framework applicable
to biotechnology, evaluate the risks of adaptation,
determine the level of protection desired, and ensure
the existence of national institutions capable of
carrying out the relevant tasks. The dynamic
development of science, the national standards and
regulations established and the level of risk
involved, however, make it necessary for the
institutions to formulate new regulations and make
constant revisions of existing ones in order to
supplement and expand the rules designed to ensure
the safety of consumers.
The developing countries also need capacity for
adaptation, implementation, dissemination and
innovation in a sector which is accessible but of high
technology. They therefore need research institutions
which will not only fulfill their own objectives but will
also carry out the function of bringing investors and
creators of technology closer to consumers.
Biotechnological development benefits producers,
directly satisfies consumers’ needs and involves both
benefits and risks for the agricultural sector. In order to
attain food security, however, it would be desirable for
the developing countries, and especially their resource-
poor farmers, to derive more benefits from advances in
biotechnology, to have greater access to sources of genetic
resources and public finance, and to receive the fruits of a
better dialogue between the public and private sectors (FAO,
2000).
The confidence of consumers in the institutions
which recommend standards is increasingly important
for the decisions they take. Lack of transparency and
clarity of the rules adopted and delays in taking suitable
measures to deal with problems as they arise are
elements that militate against this.
The different views regarding transgenic products
are a source of concern. For the United States, only the
final product and not the production process can be the
subject of regulation; for the European Union, in
contrast, both the final product and the production
process should be subject to regulation. The tendency
to regulate the production process is a source of dispute,
since such regulation is not accepted by the WTO.
The SPM and TBT Agreements provide lines along
which countries can guide their regulations on the basis
of science and settle their differences at the bilateral
level, avoiding the need to bring them before the WTO.
They also make it possible to harmonize the different
national regulatory systems and labelling requirements,
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but they do not provide a solution if the conflict is based
on ethical considerations, without scientific evidence
to justify demanding special labels. This may make
necessary the revision of both agreements and lead to
further negotiations in the WTO.
The approval of the Protocol does not eliminate
the possibility of future problems, but it does indicate
that the arguments for and against the use of the new
techniques are gradually beginning to draw closer to
each other. Steps have begun to be taken towards
convergence between the different positions which, on
the one hand, promise more plentiful food and, on the
other, fear the possible effects of the consumption of
transgenic products on health and the environment. This
does not mean that the debate is over, however, since
some countries consider that the Protocol is insufficient
and want to continue research in order to achieve safer
trade in biotechnological products.
The question of new agricultural products is under
discussion in international forums and repeatedly turns
up in negotiations. The trade disputes over labelling
and the different national regulations do nothing to
reduce the uncertainty. Labels do not say what genes
are incorporated in products; the uncertainty over the
risks involved in the consumption of modified products
will very likely continue, and it will be necessary to
negotiate over what information should be included in
order to give greater transparency. The uncertainty over
the consumption of such products could be reduced if
the wording of labels is precise, free of any form of
manipulation, simple and balanced.
An element which helps to keep the debate alive is
the fact that the Latin American countries possess great
biodiversity, which currently provides large profits that
go mainly into the pockets of the transnational
corporations, without the countries of the region
receiving the share that corresponds to them for giving
access to the genetic inputs in question. The question of
sharing out the profits has not been settled, and it does
not seem that an easy solution can be reached in the short
term. So far, the arguments usually stress the concerns
of the countries that make the greatest use of
biotechnology, neglecting the concerns and interests of
the developing countries.
Finally, it cannot be concluded a priori that a
foodstuff should be classed as harmful or beneficial,
good or bad, deleterious or harmless simply because it
is transgenic. Every new foodstuff must be subjected
to exhaustive analysis before it is placed on the market.
It is essential that the risks and benefits of each of the
transgenic organisms involved and their repercussions
on national ecosystems should be dispassionately
evaluated and the conclusions passed on to society. This
will pave the way for further progress in the creation
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